SCHEMBL10073789

SCHEMBL10073789

Nc1ccc2c(Oc3ccc(NC(=O)Nc4ccccc4)cc3)cncc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 5/20 0.57
IMPDH2 P12268 1/20 0.48
KDR P35968 2/20 0.47
PDGFRA P16234 1/20 0.47
FLT3 P36888 1/20 0.46
IGF1R P08069 1/20 0.45
BRAF P15056 1/20 0.44
MAPK14 Q16539 1/20 0.44
CDK8 P49336 6/20 0.43
ICAM1 P05362 2/20 0.43
SELE P16581 2/20 0.43
CCNC P24863 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
VCAM1 P19320 1/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717713 0.87 ICAM1 (0.51) CSF1RCDK8ICAM1SELECCNC
SCHEMBL282624 0.83 CDK8 (0.61) CSF1RKDRPDGFRAFLT3BRAF
SCHEMBL282579 0.82 CDK8 (0.61) KDRPDGFRAFLT3BRAFCDK8
SCHEMBL281698 0.82 RAF1 (0.50) KDRPDGFRAFLT3BRAFCDK8
SCHEMBL282422 0.80 ICAM1 (0.50) CDK8ICAM1SELECCNCVCAM1
SCHEMBL10084374 0.77 CSF1R (0.54) CSF1RKDRPDGFRAFLT3BRAF
SCHEMBL5550589 0.75 ICAM1 (0.77) CDK8ICAM1SELECCNCVCAM1
SCHEMBL281915 0.74 CDK8 (0.48) KDRPDGFRAFLT3BRAFCDK8
SCHEMBL21305504 0.72 DDX3X (0.68) CSF1RCDK8CA12CA1CA2
SCHEMBL18586470 0.70 CA12 (0.70) CSF1RCDK8CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957087-B2 Heterocyclic substituted acardite derivate and application thereof Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) 2015-02-17 US disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 CSF1R 2180/4885IMPDH2 390/4885KDR 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.